What this trial studies
Menopause is defined as the permanent cessation of menstruation as a result of the loss of ovarian follicular function. This process involves some bothersome physical and psychological climacteric symptoms. The most common symptoms are vasomotor symptoms, psychological symptoms and sleep disturbances. The aim of this study is to investigate the effects of CTM on postmenopausal symptoms, menopause-specific quality of life (MENQoL) and insomnia.
Conditions in scope
- Menopause Syndrome
Interventions
- Connective tissue manipulation (Other) — Connective tissue manipulation will be applied to participants' back for 5-20 minutes, 3 times a week for 4 weeks in this group.
- Superficial massage with the head of the therapeutic ultrasound device (Other) — Superficial massage with the head of the therapeutic ultrasound device will be applied to participants' back for 15 minutes, 3 times a week for 4 weeks in this group.
Who can join
Women only · Ages 45 Years to 65 Years
Inclusion criteria
- Aged between the 45 and 65 years,
- Being experienced at least 3 moderate or severe hot flashes, sweating or night sweats per day for at least 3 months,
- Being in the natural/spontaneous postmenopausal (amenorrhea for at least 12 months) period for less than 10 years,
- Having stable vital signs (heart rate, blood pressure),
- Volunteer to participate in the study,
- Have signed the informed consent form.
Exclusion criteria
- Neurological diseases,
- Uncontrolled systemic and metabolic diseases (uncontrolled diabetes mellitus, hypertension, etc.)
- History of cancer,
- History of surgical menopause,
- Obesity (BMI \> 35 kg/m²),
- Use of any hormonal or non-hormonal treatment for vasomotor or other menopausal symptoms in the past 6 months,
- Psychiatric and mental disorders that prevent the cooperation to the study.
Eligibility wording paraphrased from the public record. View the full criteria on ClinicalTrials.gov before contacting a site.
Where it’s happening
| City | State / Region | Facility | Site status |
|---|---|---|---|
| Ankara | Hacettepe University | Unknown |
Status & timeline
- Overall status: Completed
- Study type: Interventional
- Phase: N/A
- Start date: 2022-04-15
- Primary completion: 2023-04-26
- Last update posted: 2024-09-25
- First posted: 2022-03-24
Sponsor & contact
Lead sponsor: Hacettepe University (Other)
Collaborators: Hitit University
For trial site contact information, use the official record at ClinicalTrials.gov. Contact details change frequently and the public record is the source of truth.
Outcome measures
Primary outcomes
- Severity of menopausal symptoms (Change in the severity of menopausal symptoms from baseline to at the end of the 4th week.)
The severity of menopausal symptoms will be evaluated with the Menopause Rating Scale (MRS). MRS was developed to assess the severity of 11 symptoms associated with menopause. Each of the 11 symptoms may score between 0 (no symptoms) and 4 points (severe symptoms), depending on the perceived severity of the complaints. The total score of the MRS ranges between 0…
Related ClearedRx care
If you’re reading this trial because you have menopause symptoms now, you don’t have to wait for a trial to access evidence-based care. ClearedRx prescribes the same FDA-approved and compounded HRT products that have been studied in trials like this one for decades.
Important. Information from ClinicalTrials.gov as of May 8, 2026. Trial details (status, sites, contacts, eligibility, outcomes) change frequently — always check the official record at https://clinicaltrials.gov/study/NCT05293860 before contacting a site.
ClearedRx is not affiliated with this trial or its sponsor. We index public-domain ClinicalTrials.gov records to help patients find evidence-based context for menopause care decisions. ClearedRx itself is a telehealth menopause/HRT brand — we do not enroll patients in trials.